Policy News
-
UNIVERSITY OF UTAH HEALTH DEDICATES JAMES LEVOY SORENSON CENTER FOR MEDICAL INNOVATION
Apr 14, 2026 University of Utah Health dedicated the James LeVoy Sorenson Center for Medical Innovation, a $50-million…
-
Sen. Mike Lee’s Deputy Chief Tours Sorenson Center for Medical Innovation
Senator Lee’s Deputy chief of staff Justin Anthony yesterday toured the new James LeVoy Sorenson Center for Medical…
-
ARUP Advocates for the RESULTS Act To Protect Patient Access to Critical Laboratory Testing Services
SALT LAKE CITY, November 19, 2025— With a deadline approaching on January 31, 2026, ARUP Laboratories has joined…
-
Recap: 2025 Mayer Brown Utah Life Sciences Summit
The 2025 BioUtah Utah Life Sciences Summit (ULSS) took place November 12 at the Hilton Salt Lake City…
-
EDWARDS LIFESCIENCES ANNOUNCES $500 MILLION ACCELERATED SHARE REPURCHASE
IRVINE, Calif.–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced that it has executed an accelerated share repurchase agreement…
-
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval.
-
Webinar Recap: Immigration Compliance Under Pressure
As immigration enforcement and workplace inspections intensify under the current administration, companies in the life sciences sector, particularly…
-
2025 BIO International Recap
BioUtah and its Utah consortium made their mark this week at the BIO International Conference, hosting a Utah…
-
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular…
-
BioUtah Award Winners and Utah Rare Disease Advisory Council Take Center Stage at Utah Life Sciences Innovation Caucus
More than a dozen Utah legislators on Wednesday, November 20, held a breakfast meeting of the Utah Life…
-
BioUtah and Coalition of Patient Advocates Talk PBM Reform with U.S. Reps. Blake Moore and Celeste Maloy
BioUtah’s VP for Government Affairs, Denise Bell, along with a coalition of patient advocates, life sciences executives, pharmacists,…
-
UTAH REPS. CURTIS AND MOORE TOUR BIOMERIEUX
Representatives John Curtis (R-UT) and Blake Moore (R-UT) toured bioMérieux.
-
bioMeriéux, Curza, Present to Utah Life Sciences Innovation Caucus
Utah legislators on Wednesday, August 21, held a meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at…
-
ARUP Statement on FDA Final Rule to Regulate Laboratory-Developed Tests as Medical Devices
ARUP maintains that the FDA’s rule will limit access to testing, stifle innovation, and increase healthcare costs.
-
Ingenion Medical Obtains CE Mark for Catheter
The cymactive catheter is the first in a pipeline of urology solutions the UK-based company has planned.
-
Anbex Awarded Bid from Hong Kong’s Department of Health
Anbex Awarded Bid from Hong Kong’s Department of Health
-
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers
-
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics
Funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome…
-
Seek Labs Unveils SeekIt™
Seek Labs’ integrated molecular diagnostic platform brings true point-of-care testing to the patient.
-
ELITechGroup obtains new IVDR certificate for PCR assays
After the release of the first IVDR certificate at the beginning of the year ELITech Group continues to…
-
Bloom Surgical Awarded Competitive Grant from the NSF
Funding accelerates development of device for resolving visual disruptions in robotic procedures Salt Lake City, UT, June 1,…
-
Rep. Moore Calls For Increased Transparency in the NCD Process
Utah U.S. Rep. Blake Moore (R-UT) signed onto a letter to HHS/CMS, led by House Ways and Means…
-
Denali Therapeutics, Alucent Biomedical, Present to Utah Life Sciences Innovation Caucus
Utah legislators on Wednesday, June 14, held a meeting of the Utah Life Sciences Innovation Caucus (ULSIC) at…
-
House Health Panel Advances Legislation on PBM’s, Generic Drugs
The Energy and Commerce Health Subcommittee on Wednesday voted to advance a series of healthcare bills, largely on a bipartisan…
-
Representative Blake Moore Stands Up for Innovation
The House Ways and Means Subcommittee on Health on May 10 held a hearing examining government policies that…
-
Recap of 2023 E&I Summit
The 2023 Wilson Sonsini Entrepreneur & Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University…
-
BioUtah Recognizes 2023 Rare Disease Day
BioUtah on Feb. 28 joined Utah’s rare disease community, including patients, families and advocates, in recognizing 2023 Rare…
-
HHS Releases New Payment Models for Prescription Drugs
HHS released on Tuesday, three new payment models that will be tested through the Centers for Medicare &…
-
HEALTHCARE POLICY FIGURES PROMINENTLY IN $1.7 TRILLION OMNIBUS GOVERNMENT FUNDING BILL
Congress is expected to vote this week on a massive omnibus government funding bill that would run through…
-
Sen. Lee Introduces Bill to Increase Patient Access to Biosimilars
On November 17, Sen. Mike Lee (R-UT) introduced the “Biosimilar Red Tape Elimination Act” to increase patient access…
-
Senator Mike Lee Introduces Bill to Roll Back Government Drug Price Controls
Senator Mike Lee (R-UT) has introduced the “Protecting Drug Innovation Act” which would roll back Medicare’s authority to…
-
Senator Mike Lee Urges Action for Transitional Coverage of Innovative Med Tech
Senator Mike Lee (R-UT) and a group of like-minded colleagues are preparing to send a letter to CMS…
-
Senator Mike Lee Spends a Day in the BioHive
U.S. Senator Mike Lee (R-UT) on August 15 spent the day connecting with Utah’s life sciences community, known…
-
Tillis and Leahy Introduce Bipartisan Legislation to Improve Patent Quality
Tillis and Leahy Introduce Bipartisan Legislation to Improve Patent Quality
-
Senate Democrats Push Drug Pricing, Tax, Climate Package
Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better”…
-
BioUtah Joins State BIOs in Opposing Drug Price Controls
Senate Democrats are inching closer to a vote on a revived “Build Back Better” package, largely focused on…
-
Senate Democrats Renew Plan for Drug Price Controls
Senate Democrats have renewed a push for drug pricing reforms, releasing on Wednesday proposed legislation along with a…
-
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, recently announced that the FDA granted Orphan…
-
Sumitomo Pharma Oncology, Inc. Pursues Research and Discovery with Persistence – Featured in Pharma Tech Outlook
Sumitomo Pharma Oncology, Inc. (SMP Oncology) and Steve Warner, Ph.D., Senior Vice President and Head of US Research…
-
Sen. Romney Opposes Drug Importation as the Senate HELP Committee Advances User Fees
The Senate Health, Education, Labor and Pensions (HELP) Committee voted 13 to 9 on Tuesday to advance user…
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8M Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial…
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
